Literature DB >> 21544739

EATRIS, a vision for translational research in Europe.

Regina Becker1, Guus A M S van Dongen.   

Abstract

Tremendous progress has been made in biomedical research in genomics, proteomics and metabolomics, which has led to an increasing insight into molecular mechanisms related to diseases. Yet the output of disease prevention, diagnosis and treatment solutions remains low. It is against this background that several European countries have gathered to take new actions for improving translational research from bench to bedside. Surveys were conducted to identify major bottlenecks and assess the situation of translational research in Europe. While the importance of translational research is already recognized and national governments have increased their efforts and academia more and more directs its research towards translation, there are still hurdles to overcome. Thus, a European research infrastructure-EATRIS-will be established to integrate basic and clinical research in dedicated translational centres. These EATRIS Centres will provide broad access to high-end pre-clinical and clinical facilities, including the necessary translational expertise for researchers from academia and industry.

Mesh:

Year:  2011        PMID: 21544739     DOI: 10.1007/s12265-011-9260-8

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  5 in total

1.  Obstacles facing translational research in academic medical centers.

Authors:  J S Pober; C S Neuhauser; J M Pober
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

Review 2.  Immuno-positron emission tomography: shedding light on clinical antibody therapy.

Authors:  Guus A M S van Dongen; Maria J W D Vosjan
Journal:  Cancer Biother Radiopharm       Date:  2010-08       Impact factor: 3.099

3.  Driving drug discovery: the fundamental role of academic labs.

Authors:  B Michael Silber
Journal:  Sci Transl Med       Date:  2010-05-05       Impact factor: 17.956

Review 4.  Challenges with advanced therapy medicinal products and how to meet them.

Authors:  Christian K Schneider; Paula Salmikangas; Bernd Jilma; Bruno Flamion; Lyubina Racheva Todorova; Anna Paphitou; Ivana Haunerova; Toivo Maimets; Jean-Hugues Trouvin; Egbert Flory; Asterios Tsiftsoglou; Balázs Sarkadi; Kolbeinn Gudmundsson; Maura O'Donovan; Giovanni Migliaccio; Jānis Ancāns; Romaldas Maciulaitis; Jean-Louis Robert; Anthony Samuel; Johannes H Ovelgönne; Marit Hystad; Andrzej Mariusz Fal; Beatriz Silva Lima; Anca Stela Moraru; Peter Turcáni; Robert Zorec; Sol Ruiz; Lennart Akerblom; Gopalan Narayanan; Alastair Kent; Fabrizia Bignami; J George Dickson; Dietger Niederwieser; María-Angeles Figuerola-Santos; Ilona G Reischl; Claire Beuneu; Rosen Georgiev; Maria Vassiliou; Alena Pychova; Mette Clausen; Taina Methuen; Sophie Lucas; Martina Schüssler-Lenz; Vasilios Kokkas; Zsuzsanna Buzás; Niall MacAleenan; Maria Cristina Galli; Aija Linē; Jolanta Gulbinovic; Guy Berchem; Mariusz Fraczek; Margarida Menezes-Ferreira; Nela Vilceanu; Mikulás Hrubisko; Petra Marinko; Marcos Timón; Wing Cheng; George Andrew Crosbie; Nick Meade; Michelino Lipucci di Paola; Thierry VandenDriessche; Per Ljungman; Lucia D'Apote; Olga Oliver-Diaz; Isabel Büttel; Patrick Celis
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

5.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Authors:  Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

  5 in total
  2 in total

1.  EATRIS, a European initiative to boost translational biomedical research.

Authors:  Guus Ams van Dongen; Anton E Ussi; Frank H de Man; Giovanni Migliaccio
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

Review 2.  A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.

Authors:  Rebecca A Crow; Kimberly A Hart; Michael P McDermott; Rabi Tawil; William B Martens; Barbara E Herr; Elaine McColl; Jennifer Wilkinson; Janbernd Kirschner; Wendy M King; Michele Eagle; Mary W Brown; Deborah Hirtz; Hanns Lochmuller; Volker Straub; Emma Ciafaloni; Perry B Shieh; Stefan Spinty; Anne-Marie Childs; Adnan Y Manzur; Lucia Morandi; Russell J Butterfield; Iain Horrocks; Helen Roper; Kevin M Flanigan; Nancy L Kuntz; Jean K Mah; Leslie Morrison; Basil T Darras; Maja von der Hagen; Ulrike Schara; Ekkehard Wilichowski; Tiziana Mongini; Craig M McDonald; Giuseppe Vita; Richard J Barohn; Richard S Finkel; Matthew Wicklund; Hugh J McMillan; Imelda Hughes; Elena Pegoraro; W Bryan Burnette; James F Howard; Mathula Thangarajh; Craig Campbell; Robert C Griggs; Kate Bushby; Michela Guglieri
Journal:  Trials       Date:  2018-05-10       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.